Hunan Fangsheng Pharmaceutical Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Hunan Fangsheng Pharmaceutical Co., Ltd. carries a market capitalization of 4.27B, placing it among publicly traded companies globally. Its enterprise value stands at 4.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.27B |
| Enterprise Value | 4.81B |
Share Statistics
Hunan Fangsheng Pharmaceutical Co., Ltd. currently has 439.08M shares outstanding.
| Shares Outstanding | 439.08M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Hunan Fangsheng Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 15.07. The price-to-sales ratio is 2.55, and the price-to-book ratio stands at 3.25.
| PE Ratio | 15.07 |
| PS Ratio | 2.55 |
| PB Ratio | 3.25 |
| P/TBV Ratio | 3.64 |
| P/FCF Ratio | 53.99 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Hunan Fangsheng Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 16.55 and an EV/FCF ratio of 49.58. The EV/Sales ratio of 2.82 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.55 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.82 |
| EV / EBITDA | 16.55 |
| EV / EBIT | 16.55 |
| EV / FCF | 49.58 |
Financial Position
Hunan Fangsheng Pharmaceutical Co., Ltd. maintains a current ratio of 0.81, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.59, indicating elevated leverage, while an interest coverage ratio of 15.44 demonstrates strong ability to service its debt obligations.
| Current Ratio | 0.81 |
| Quick Ratio | 0.12 |
| Debt / Equity | 31.59 |
| Debt / EBITDA | 1.86 |
| Interest Coverage | 15.44 |
Financial Efficiency
Hunan Fangsheng Pharmaceutical Co., Ltd. posts a return on equity of 22.68 and a return on invested capital of 10.98.
| Return on Equity (ROE) | 22.68 |
| Return on Assets (ROA) | 9.15 |
| Return on Invested Capital (ROIC) | 10.98 |
| Return on Capital Employed (ROCE) | 15.45 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.32 |
Taxes
Over the trailing twelve months, Hunan Fangsheng Pharmaceutical Co., Ltd. has paid 36.58M in income taxes, reflecting an effective tax rate of 11.53.
| Income Tax | 36.58M |
| Effective Tax Rate | 11.53 |
Stock Price Statistics
Hunan Fangsheng Pharmaceutical Co., Ltd.'s stock has declined approximately -5.3554% over the past 52 weeks. The 50-day moving average sits at 10.11, while the 200-day moving average is 11.33.
| Beta (5Y) | N/A |
| 52-Week Price Change | -5.3554% |
| 50-Day Moving Average | 10.11 |
| 200-Day Moving Average | 11.33 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hunan Fangsheng Pharmaceutical Co., Ltd. generated 1.70B in revenue and converted that into 287.61M in net income, yielding earnings per share of 0.64. EBITDA reached 290.42M, while operating income came in at 290.42M.
| Revenue | 1.70B |
| Gross Profit | 1.20B |
| Operating Income | 290.42M |
| Pretax Income | 317.28M |
| Net Income | 287.61M |
| EBITDA | 290.42M |
| EBIT | 290.42M |
| Earnings Per Share (EPS) | 0.64 |
Balance Sheet
Hunan Fangsheng Pharmaceutical Co., Ltd. holds 145.87M in cash and equivalents against 541.64M in total debt, resulting in a net debt position of 389.58M. Total book value stands at 1.33B, with working capital of -227.47M providing operational flexibility.
| Cash & Cash Equivalents | 145.87M |
| Total Debt | 541.64M |
| Net Debt | 389.58M |
| Equity (Book Value) | 1.33B |
| Book Value Per Share | 3.02 |
| Working Capital | -227.47M |
Cash Flow
After subtracting -80.27M in capital expenditures, free cash flow totaled -80.27M - equivalent to -0.18 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -80.27M |
| Free Cash Flow | -80.27M |
| FCF Per Share | -0.18 |
Margins
Hunan Fangsheng Pharmaceutical Co., Ltd. operates with a gross margin of 70.65, reflecting its pricing power and cost economics. The operating margin of 17.07 and net profit margin of 16.90 provide insight into operational efficiency.
| Gross Margin | 70.65 |
| Operating Margin | 17.07 |
| Pretax Margin | 18.65 |
| Profit Margin | 16.90 |
| EBITDA Margin | 17.07 |
Dividends & Yields
The company's payout ratio of 53.09 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.33 |
| Dividend Yield | N/A |
| Payout Ratio | 53.09 |
| Shareholder Yield | 9.71 |
| FCF Yield | 1.85 |
Stock Splits
Hunan Fangsheng Pharmaceutical Co., Ltd.'s most recent stock split took place on May 5, 2016 with a 1:3 split ratio.
| Last Split Date | 5/5/2016 |
| Split Ratio | 1:3 |
Scores
Hunan Fangsheng Pharmaceutical Co., Ltd. posts an Altman Z-Score of 3.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.37 |